DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025" report to their offering.
Heart Failure Market to Soar to $11.8 Billion by 2025 as Effective New Drugs Become Available
This report provides analysis of the heart failure space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2015 and forecast to 2025. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute heart failure therapeutics arenas.
The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7%, according to research and consulting firm.
The key drivers of this substantial growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be the launch of Novartis' first-in-class drug, Entresto, and several acute heart failure add-on therapies, as well as an increase in the global prevalence of chronic heart failure.
Novartis' Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), which was launched in the US in 2015 and the five European countries in 2016, and is set for release in Japan by 2020. The drug has raised the benchmark for efficacious chronic heart failure therapy, although uptake has been slow.
Entresto has struggled to penetrate the chronic heart failure market, achieving dismal sales in the US since its launch in July 2015. The author has identified high pricing and the general reluctance of cardiologists and physicians to adopt new therapies as the main barriers to the uptake of this drug. Despite this, it is expected that Entresto will begin to dominate the global heart failure space, particularly after its label expansion to heart failure with preserved ejection fraction, which is expected to occur in 2020, making it the strongest driver of market growth.
Despite these significant advances for chronic heart failure, particularly with reduced ejection fraction, there have been no advances in the treatment of acute heart failure for the past two decades. However, two drugs currently undergoing Phase III evaluation for the treatment of acute heart failure have the potential to shape how this condition is treated.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunities
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
11 Appendix
Companies Mentioned
- Novartis
- Les Laboratoires Servier
- Cardiorentis
- Bayer (and Merck & Co.)
- Cytokinetics
For more information about this report visit http://www.researchandmarkets.com/research/6sw464/pharmapoint
